| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 12/24/2003 | WO2003090662A3 Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease |
| 12/24/2003 | WO2003089593A3 Adjuvant enhanced immunotherapy |
| 12/24/2003 | WO2003089568A3 Method of inhibiting restenosis |
| 12/24/2003 | WO2003089007B1 Pharmaceutical compositions comprising a decongenstant and further active ingredients for treating cough and flu |
| 12/24/2003 | WO2003088765A3 Functional foods containing a phospholipid-containing stable matrix |
| 12/24/2003 | WO2003087298A3 Nucleosides preparation thereof and use as inhibitors of rna viral polymerases |
| 12/24/2003 | WO2003086396A9 Phosphodiesterase iv inhibitor containing pyridylacrylamide derivative |
| 12/24/2003 | WO2003084940B1 Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors |
| 12/24/2003 | WO2003084916A3 Compounds that modulate ppar activity and methods for their preparation |
| 12/24/2003 | WO2003084519A3 Aerosol formulation for inhalation comprising a tiotropium salt |
| 12/24/2003 | WO2003084462A3 Process for preparation of pharmaceutical composition containing antiretroviral protease inhibitor with improved bioavailability |
| 12/24/2003 | WO2003083113A3 Growth regulating proteins |
| 12/24/2003 | WO2003082807A3 Amino acids with affinity for the alpha-2-delta-protein |
| 12/24/2003 | WO2003082340B1 Injectable veterinary composition for small animals |
| 12/24/2003 | WO2003082257A3 Method for treating ocular hypertension and glaucoma |
| 12/24/2003 | WO2003082248A3 Taste masked compositions of erythromycin a and derivatives thereof |
| 12/24/2003 | WO2003079020A3 Methods and compositions for the identification, assessment, and therapy of small cell lung cancer |
| 12/24/2003 | WO2003077892A3 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide for treating ang ii-mediated diseases |
| 12/24/2003 | WO2003076414A3 Aryl substituted pyrimidines and the use thereof |
| 12/24/2003 | WO2003075926A8 Use of proton pump inhibitors for the treatment of airway disorders |
| 12/24/2003 | WO2003075828A3 Compounds useful in the treatment of cancer |
| 12/24/2003 | WO2003075015A3 Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents |
| 12/24/2003 | WO2003074529A3 iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS |
| 12/24/2003 | WO2003074025A3 Pressurised metered dose inhalers containing solutions of beta-2 agonists |
| 12/24/2003 | WO2003072558A3 Arylsulfone derivatives |
| 12/24/2003 | WO2003072548A8 Pyridyl sulfone derivatives as 5-ht receptor antagonists |
| 12/24/2003 | WO2003072050A3 Prevention of and therapy for radiation toxicity of normal tissues using drugs which block il-1 activity |
| 12/24/2003 | WO2003072028A3 Method of treating hiv infection by preventing interaction of cd4 and gp120 |
| 12/24/2003 | WO2003072026A3 Method of reducing and treating uvb-induced immunosuppression |
| 12/24/2003 | WO2003070914A3 RNA INTERFERENCE MEDIATED INHIBITION OF FOS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 12/24/2003 | WO2003070182A3 Sodium channel blockers |
| 12/24/2003 | WO2003070180A3 Compositions and methods for delivery of skin cosmeceuticals |
| 12/24/2003 | WO2003070153A3 Stabilized pharmaceutical compositions of halofuginone and other quinazolinone derivatives |
| 12/24/2003 | WO2003068760A3 Compounds possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders |
| 12/24/2003 | WO2003068725A3 Process for the preparation of 4-hetero-substituted phenylalanine derivatives |
| 12/24/2003 | WO2003068231A3 Preparations containing folic acid, vitamin b6, and vitamin b12, and use thereof |
| 12/24/2003 | WO2003068224A3 Use of inhibitors of the sodium-dependent chloride-bicarbonate-exchanger for treating thrombotic and inflammatory diseases |
| 12/24/2003 | WO2003068166A3 Treatment of ophthalmic disorders using urea and urea derivatives |
| 12/24/2003 | WO2003066840A3 Pluripotent embryonic-like stem cells derived from teeth and uses thereof |
| 12/24/2003 | WO2003066806A3 Therapeutic use of aziridino compounds |
| 12/24/2003 | WO2003066659A3 Improved method for obtaining betulinic acid |
| 12/24/2003 | WO2003066048A3 Use of 15-lipoxygenase inhibitors for treating and preventing bone loss |
| 12/24/2003 | WO2003064685A3 Genetic polymorphisms in the preprotachykinin gene |
| 12/24/2003 | WO2003064394A8 5-ring heterocycles used as antiviral agents |
| 12/24/2003 | WO2003063831A3 Immediate release dosage forms containing solid drug dispersions |
| 12/24/2003 | WO2003063826A3 Ophthalmic compositions including oil-in-water emulsions, and methods for making and using the same |
| 12/24/2003 | WO2003063800A3 8-heteroaryl xanthine adenosine a2b receptor antagonists |
| 12/24/2003 | WO2003063757A3 Auger effect-based cancer therapy method |
| 12/24/2003 | WO2003062236A8 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES |
| 12/24/2003 | WO2003061703A9 Methods for treatment of multiple sclerosis with statins |
| 12/24/2003 | WO2003061653A9 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases |
| 12/24/2003 | WO2003061567A3 Selective s1p1/edg1 receptor agonists |
| 12/24/2003 | WO2003057162A3 Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases |
| 12/24/2003 | WO2003055896A3 Anti-viral 7-deaza l-nucleosides |
| 12/24/2003 | WO2003053361A3 PYRROLOPYRIMIDINE A2b SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE |
| 12/24/2003 | WO2003053335A3 Methods of attenuating cognitive deficits with sulfonyl fluorides |
| 12/24/2003 | WO2003051299A3 Sulfhydryl rifamycins and uses thereof |
| 12/24/2003 | WO2003048148A9 Statin-like compounds |
| 12/24/2003 | WO2003047611A3 Ptp10d, tec and edtp involved in triglycerid-metabolism |
| 12/24/2003 | WO2003045429A3 Anti-t cell immunotoxin fusion protein and its therapeutic use |
| 12/24/2003 | WO2003043579A3 Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions |
| 12/24/2003 | WO2003040294A3 METHOD FOR THE IN VITRO SYNTHESIS OF SHORT DOUBLE STRANDED RNAs |
| 12/24/2003 | WO2003040174A3 Substituted amino ketone compounds |
| 12/24/2003 | WO2003037886A3 Heteroaromatic carboxamide derivatives for the treatment of inflammation |
| 12/24/2003 | WO2003037362A3 Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism |
| 12/24/2003 | WO2003037296A3 Methods and dosage forms for improving the bioavailability of therapeutic agents |
| 12/24/2003 | WO2003035666A3 Phosphorothioate-modified oligonucleotide as anti-restenosis agent |
| 12/24/2003 | WO2003035137A3 Method and apparatus for dispensing inhalator medicament |
| 12/24/2003 | WO2003035046A3 Salts formed of an at1-receptor antagonist and a cardiovascular agent |
| 12/24/2003 | WO2003033048A3 Drug delivery system for conscious sedation |
| 12/24/2003 | WO2003032963A3 Method of reducing type 2 diabetes in high risk patients |
| 12/24/2003 | WO2003028701A3 Liposomes containing (ether)lysolecithins |
| 12/24/2003 | WO2003027322A3 Hepatocellular carcinoma-related genes and polypeptides, and method for detecting hepatocellular carcinomas |
| 12/24/2003 | WO2003022239A3 Stable water in oil aminophylline emulsions |
| 12/24/2003 | WO2003022207A3 Method and composition for reducing sebum secretion in mammals |
| 12/24/2003 | WO2003020280B1 Compositions and use thereof in the treatment of cancer |
| 12/24/2003 | WO2003018626A3 Novel genetic products from ashbya gossypii, associated with the structure of the cell wall or the cytoskeleton |
| 12/24/2003 | WO2003017975A3 Method for producing solutions |
| 12/24/2003 | WO2003015614A3 Use of clc3 chloride channel blockers to modulate vascular tone |
| 12/24/2003 | WO2003011846B1 Process for the preparation of 5-substituted isobenzofurans |
| 12/24/2003 | WO2003009871A3 Inhibitors of plasminogen activator inhibitor for decreasing body mass |
| 12/24/2003 | WO2003007914A3 Biocompatible polymer containing composition for treatment of prostate cancers |
| 12/24/2003 | WO2003000235A9 Pharmaceutical compositions of dispersions of drugs and neutral polymers |
| 12/24/2003 | WO2002100858A8 Quinuclidine-substituted heteroaromatic compounds as ligands at nicotinic acetylcholine receptors |
| 12/24/2003 | WO2002090356A3 Method for the production of zolpidem |
| 12/24/2003 | WO2002085901A8 Substituted azabicyclic moieties for the treatment of disease (nicotinic acethylcholine receptor agonists) |
| 12/24/2003 | WO2002074241A3 Method of delaying ejaculation |
| 12/24/2003 | WO2002068561A8 Cubic liquid crystalline phase precursor |
| 12/24/2003 | WO2002068548A8 Use of erss-selective ligands for regulating fertility and compounds useful therefore |
| 12/24/2003 | WO2002067994A3 Compounds comprising an analgesic molecule linked to a vector that can vectorise said molecule through the hematoencephalic barrier and pharmaceutical compositions containing same |
| 12/24/2003 | WO2002066037A8 Antiviral method of use |
| 12/24/2003 | WO2002060483A3 Perylenequinones for use as photosensitizers and sonosensitizers |
| 12/24/2003 | WO2002058692A3 Halogenated composition, method for preparing same and uses thereof |
| 12/24/2003 | WO2002047611A3 Cddo-compounds and combination therapies thereof |
| 12/24/2003 | WO2002046147A3 Perturbed membrane-binding compounds |
| 12/24/2003 | WO2002040006A3 Treatment of anxiety disorders |
| 12/24/2003 | WO2002034204A8 Calcilytic compounds |
| 12/24/2003 | WO2002018540A3 Pyridine derivatives useful as cd40:cd154 binding interruptor compounds and use thereof to treat immunological complications |
| 12/24/2003 | WO2002015897A3 Use of sublethal concentrations of anti-invasin compounds to therapeutically or prophylactically treat fungal infections |
| 12/24/2003 | WO2001092542A8 Integrin-targeting vectors having enhanced transfection activity |